ATP. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom